University of Tasmania
Browse
82084 - Blocking the effects of interleukin-6 in rheumatoid arthritis.pdf (309.39 kB)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Download (309.39 kB)
journal contribution
posted on 2023-05-17, 15:24 authored by Schoels, MM, van der Heijde, D, Breedveld, FC, Burmester, GR, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez-Reino, JJ, Graeme JonesGraeme Jones, Kvien, TK, Murikama, MM, Nishimoto, N, Smolen, JS

Background: Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

Objective: To review published evidence on safety and efficacy of IL-6i in inflammatory diseases.

Methods: We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov.

Results: Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable.

Conclusions: IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.

History

Publication title

Annals of the Rheumatic Diseases

Volume

72

Pagination

583-589

ISSN

0003-4967

Department/School

Menzies Institute for Medical Research

Publisher

B M J Group

Place of publication

United Kingdom

Rights statement

Copyright 2013 BMJ

Repository Status

  • Open

Socio-economic Objectives

Clinical health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC